nodes	percent_of_prediction	percent_of_DWPC	metapath
Brimonidine—AOX1—prostate cancer	0.504	1	CbGaD
Brimonidine—AOX1—Ethinyl Estradiol—prostate cancer	0.193	0.608	CbGbCtD
Brimonidine—AOX1—Estradiol—prostate cancer	0.125	0.392	CbGbCtD
Brimonidine—AOX1—prostate gland—prostate cancer	0.000916	0.123	CbGeAlD
Brimonidine—AOX1—seminal vesicle—prostate cancer	0.000775	0.104	CbGeAlD
Brimonidine—Clonidine—SLC22A3—prostate cancer	0.000771	0.34	CrCbGaD
Brimonidine—AOX1—renal system—prostate cancer	0.000624	0.0841	CbGeAlD
Brimonidine—AOX1—urethra—prostate cancer	0.000613	0.0826	CbGeAlD
Brimonidine—ADRA2C—prostate gland—prostate cancer	0.000579	0.078	CbGeAlD
Brimonidine—Clonidine—SLC22A1—prostate cancer	0.000553	0.244	CrCbGaD
Brimonidine—ADRA2C—seminal vesicle—prostate cancer	0.00049	0.0659	CbGeAlD
Brimonidine—ADRA2A—prostate gland—prostate cancer	0.000462	0.0622	CbGeAlD
Brimonidine—Clonidine—CYP3A5—prostate cancer	0.000446	0.197	CrCbGaD
Brimonidine—AOX1—testis—prostate cancer	0.000404	0.0543	CbGeAlD
Brimonidine—ADRA2C—renal system—prostate cancer	0.000395	0.0531	CbGeAlD
Brimonidine—ADRA2A—seminal vesicle—prostate cancer	0.000391	0.0526	CbGeAlD
Brimonidine—ADRA2C—urethra—prostate cancer	0.000388	0.0522	CbGeAlD
Brimonidine—ADRA2A—urethra—prostate cancer	0.000309	0.0417	CbGeAlD
Brimonidine—Clonidine—CYP1A1—prostate cancer	0.000302	0.134	CrCbGaD
Brimonidine—AOX1—lymph node—prostate cancer	0.000293	0.0394	CbGeAlD
Brimonidine—ADRA2C—testis—prostate cancer	0.000255	0.0343	CbGeAlD
Brimonidine—ADRA2A—testis—prostate cancer	0.000204	0.0274	CbGeAlD
Brimonidine—Clonidine—CYP3A4—prostate cancer	0.000193	0.0852	CrCbGaD
Brimonidine—ADRA2C—lymph node—prostate cancer	0.000185	0.0249	CbGeAlD
Brimonidine—ADRA2A—lymph node—prostate cancer	0.000148	0.0199	CbGeAlD
Brimonidine—Dry skin—Doxorubicin—prostate cancer	6.27e-05	0.000495	CcSEcCtD
Brimonidine—Nausea—Goserelin—prostate cancer	6.27e-05	0.000495	CcSEcCtD
Brimonidine—Dysgeusia—Capecitabine—prostate cancer	6.26e-05	0.000494	CcSEcCtD
Brimonidine—Nausea—Conjugated Estrogens—prostate cancer	6.21e-05	0.00049	CcSEcCtD
Brimonidine—Hypersensitivity—Estradiol—prostate cancer	6.16e-05	0.000487	CcSEcCtD
Brimonidine—Bronchitis—Epirubicin—prostate cancer	6.15e-05	0.000485	CcSEcCtD
Brimonidine—Nasopharyngitis—Doxorubicin—prostate cancer	6.12e-05	0.000483	CcSEcCtD
Brimonidine—Eye disorder—Prednisone—prostate cancer	6.11e-05	0.000483	CcSEcCtD
Brimonidine—Flushing—Prednisone—prostate cancer	6.07e-05	0.000479	CcSEcCtD
Brimonidine—Hypotension—Etoposide—prostate cancer	6.06e-05	0.000478	CcSEcCtD
Brimonidine—Vision blurred—Capecitabine—prostate cancer	6.03e-05	0.000476	CcSEcCtD
Brimonidine—Asthenia—Estradiol—prostate cancer	6e-05	0.000474	CcSEcCtD
Brimonidine—Angiopathy—Prednisone—prostate cancer	5.94e-05	0.000469	CcSEcCtD
Brimonidine—Syncope—Docetaxel—prostate cancer	5.92e-05	0.000468	CcSEcCtD
Brimonidine—Pruritus—Estradiol—prostate cancer	5.92e-05	0.000467	CcSEcCtD
Brimonidine—Influenza—Doxorubicin—prostate cancer	5.91e-05	0.000467	CcSEcCtD
Brimonidine—Immune system disorder—Prednisone—prostate cancer	5.91e-05	0.000467	CcSEcCtD
Brimonidine—Arrhythmia—Prednisone—prostate cancer	5.84e-05	0.000461	CcSEcCtD
Brimonidine—Palpitations—Docetaxel—prostate cancer	5.84e-05	0.000461	CcSEcCtD
Brimonidine—Paraesthesia—Etoposide—prostate cancer	5.82e-05	0.00046	CcSEcCtD
Brimonidine—Loss of consciousness—Docetaxel—prostate cancer	5.8e-05	0.000458	CcSEcCtD
Brimonidine—Dyspnoea—Etoposide—prostate cancer	5.78e-05	0.000456	CcSEcCtD
Brimonidine—Somnolence—Etoposide—prostate cancer	5.76e-05	0.000455	CcSEcCtD
Brimonidine—Cough—Docetaxel—prostate cancer	5.76e-05	0.000455	CcSEcCtD
Brimonidine—Hypersensitivity—Mitoxantrone—prostate cancer	5.74e-05	0.000454	CcSEcCtD
Brimonidine—Syncope—Capecitabine—prostate cancer	5.73e-05	0.000453	CcSEcCtD
Brimonidine—Mental disorder—Prednisone—prostate cancer	5.73e-05	0.000453	CcSEcCtD
Brimonidine—Hypertension—Docetaxel—prostate cancer	5.7e-05	0.00045	CcSEcCtD
Brimonidine—Drowsiness—Epirubicin—prostate cancer	5.7e-05	0.00045	CcSEcCtD
Brimonidine—Erythema—Prednisone—prostate cancer	5.69e-05	0.00045	CcSEcCtD
Brimonidine—Bronchitis—Doxorubicin—prostate cancer	5.69e-05	0.000449	CcSEcCtD
Brimonidine—Palpitations—Capecitabine—prostate cancer	5.65e-05	0.000446	CcSEcCtD
Brimonidine—Arthralgia—Docetaxel—prostate cancer	5.62e-05	0.000444	CcSEcCtD
Brimonidine—Chest pain—Docetaxel—prostate cancer	5.62e-05	0.000444	CcSEcCtD
Brimonidine—Myalgia—Docetaxel—prostate cancer	5.62e-05	0.000444	CcSEcCtD
Brimonidine—Loss of consciousness—Capecitabine—prostate cancer	5.62e-05	0.000444	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Etoposide—prostate cancer	5.6e-05	0.000442	CcSEcCtD
Brimonidine—Asthenia—Mitoxantrone—prostate cancer	5.59e-05	0.000442	CcSEcCtD
Brimonidine—Fatigue—Etoposide—prostate cancer	5.59e-05	0.000441	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	5.58e-05	0.000441	CcSEcCtD
Brimonidine—Cough—Capecitabine—prostate cancer	5.58e-05	0.00044	CcSEcCtD
Brimonidine—Pain—Etoposide—prostate cancer	5.55e-05	0.000438	CcSEcCtD
Brimonidine—Conjunctivitis—Epirubicin—prostate cancer	5.54e-05	0.000437	CcSEcCtD
Brimonidine—Dizziness—Estradiol—prostate cancer	5.53e-05	0.000437	CcSEcCtD
Brimonidine—Hypertension—Capecitabine—prostate cancer	5.52e-05	0.000436	CcSEcCtD
Brimonidine—Dry mouth—Docetaxel—prostate cancer	5.5e-05	0.000434	CcSEcCtD
Brimonidine—Chest pain—Capecitabine—prostate cancer	5.44e-05	0.00043	CcSEcCtD
Brimonidine—Myalgia—Capecitabine—prostate cancer	5.44e-05	0.00043	CcSEcCtD
Brimonidine—Arthralgia—Capecitabine—prostate cancer	5.44e-05	0.00043	CcSEcCtD
Brimonidine—Anxiety—Capecitabine—prostate cancer	5.42e-05	0.000428	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	5.41e-05	0.000427	CcSEcCtD
Brimonidine—Oedema—Docetaxel—prostate cancer	5.39e-05	0.000426	CcSEcCtD
Brimonidine—Discomfort—Capecitabine—prostate cancer	5.38e-05	0.000425	CcSEcCtD
Brimonidine—Vision blurred—Prednisone—prostate cancer	5.37e-05	0.000424	CcSEcCtD
Brimonidine—Infection—Docetaxel—prostate cancer	5.35e-05	0.000423	CcSEcCtD
Brimonidine—Sinusitis—Epirubicin—prostate cancer	5.35e-05	0.000422	CcSEcCtD
Brimonidine—Dry mouth—Capecitabine—prostate cancer	5.32e-05	0.00042	CcSEcCtD
Brimonidine—Shock—Docetaxel—prostate cancer	5.3e-05	0.000419	CcSEcCtD
Brimonidine—Nervous system disorder—Docetaxel—prostate cancer	5.28e-05	0.000417	CcSEcCtD
Brimonidine—Rash—Estradiol—prostate cancer	5.28e-05	0.000417	CcSEcCtD
Brimonidine—Drowsiness—Doxorubicin—prostate cancer	5.27e-05	0.000416	CcSEcCtD
Brimonidine—Dermatitis—Estradiol—prostate cancer	5.27e-05	0.000416	CcSEcCtD
Brimonidine—Tachycardia—Docetaxel—prostate cancer	5.26e-05	0.000415	CcSEcCtD
Brimonidine—Headache—Estradiol—prostate cancer	5.24e-05	0.000414	CcSEcCtD
Brimonidine—Skin disorder—Docetaxel—prostate cancer	5.23e-05	0.000413	CcSEcCtD
Brimonidine—Oedema—Capecitabine—prostate cancer	5.22e-05	0.000412	CcSEcCtD
Brimonidine—Bradycardia—Epirubicin—prostate cancer	5.21e-05	0.000411	CcSEcCtD
Brimonidine—Infection—Capecitabine—prostate cancer	5.18e-05	0.000409	CcSEcCtD
Brimonidine—Shock—Capecitabine—prostate cancer	5.13e-05	0.000405	CcSEcCtD
Brimonidine—Rhinitis—Epirubicin—prostate cancer	5.13e-05	0.000405	CcSEcCtD
Brimonidine—Conjunctivitis—Doxorubicin—prostate cancer	5.13e-05	0.000405	CcSEcCtD
Brimonidine—Nervous system disorder—Capecitabine—prostate cancer	5.12e-05	0.000404	CcSEcCtD
Brimonidine—Syncope—Prednisone—prostate cancer	5.11e-05	0.000403	CcSEcCtD
Brimonidine—Tachycardia—Capecitabine—prostate cancer	5.09e-05	0.000402	CcSEcCtD
Brimonidine—Pharyngitis—Epirubicin—prostate cancer	5.08e-05	0.000401	CcSEcCtD
Brimonidine—Skin disorder—Capecitabine—prostate cancer	5.07e-05	0.0004	CcSEcCtD
Brimonidine—Hypotension—Docetaxel—prostate cancer	5.04e-05	0.000398	CcSEcCtD
Brimonidine—Loss of consciousness—Prednisone—prostate cancer	5.01e-05	0.000395	CcSEcCtD
Brimonidine—Nausea—Estradiol—prostate cancer	4.97e-05	0.000392	CcSEcCtD
Brimonidine—Sinusitis—Doxorubicin—prostate cancer	4.95e-05	0.000391	CcSEcCtD
Brimonidine—Visual impairment—Epirubicin—prostate cancer	4.93e-05	0.000389	CcSEcCtD
Brimonidine—Hypertension—Prednisone—prostate cancer	4.92e-05	0.000388	CcSEcCtD
Brimonidine—Rash—Mitoxantrone—prostate cancer	4.92e-05	0.000388	CcSEcCtD
Brimonidine—Dermatitis—Mitoxantrone—prostate cancer	4.91e-05	0.000388	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Docetaxel—prostate cancer	4.91e-05	0.000388	CcSEcCtD
Brimonidine—Headache—Mitoxantrone—prostate cancer	4.88e-05	0.000386	CcSEcCtD
Brimonidine—Hypotension—Capecitabine—prostate cancer	4.88e-05	0.000385	CcSEcCtD
Brimonidine—Insomnia—Docetaxel—prostate cancer	4.87e-05	0.000385	CcSEcCtD
Brimonidine—Arthralgia—Prednisone—prostate cancer	4.85e-05	0.000383	CcSEcCtD
Brimonidine—Myalgia—Prednisone—prostate cancer	4.85e-05	0.000383	CcSEcCtD
Brimonidine—Paraesthesia—Docetaxel—prostate cancer	4.84e-05	0.000382	CcSEcCtD
Brimonidine—Anxiety—Prednisone—prostate cancer	4.83e-05	0.000381	CcSEcCtD
Brimonidine—Bradycardia—Doxorubicin—prostate cancer	4.82e-05	0.000381	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	4.81e-05	0.00038	CcSEcCtD
Brimonidine—Dyspnoea—Docetaxel—prostate cancer	4.8e-05	0.000379	CcSEcCtD
Brimonidine—Somnolence—Docetaxel—prostate cancer	4.79e-05	0.000378	CcSEcCtD
Brimonidine—Discomfort—Prednisone—prostate cancer	4.79e-05	0.000378	CcSEcCtD
Brimonidine—Eye disorder—Epirubicin—prostate cancer	4.78e-05	0.000378	CcSEcCtD
Brimonidine—Hypersensitivity—Etoposide—prostate cancer	4.78e-05	0.000377	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Capecitabine—prostate cancer	4.75e-05	0.000375	CcSEcCtD
Brimonidine—Flushing—Epirubicin—prostate cancer	4.75e-05	0.000375	CcSEcCtD
Brimonidine—Cardiac disorder—Epirubicin—prostate cancer	4.75e-05	0.000375	CcSEcCtD
Brimonidine—Rhinitis—Doxorubicin—prostate cancer	4.75e-05	0.000375	CcSEcCtD
Brimonidine—Dyspepsia—Docetaxel—prostate cancer	4.74e-05	0.000375	CcSEcCtD
Brimonidine—Insomnia—Capecitabine—prostate cancer	4.72e-05	0.000373	CcSEcCtD
Brimonidine—Pharyngitis—Doxorubicin—prostate cancer	4.7e-05	0.000371	CcSEcCtD
Brimonidine—Paraesthesia—Capecitabine—prostate cancer	4.69e-05	0.00037	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Docetaxel—prostate cancer	4.65e-05	0.000367	CcSEcCtD
Brimonidine—Asthenia—Etoposide—prostate cancer	4.65e-05	0.000367	CcSEcCtD
Brimonidine—Dyspnoea—Capecitabine—prostate cancer	4.65e-05	0.000367	CcSEcCtD
Brimonidine—Oedema—Prednisone—prostate cancer	4.65e-05	0.000367	CcSEcCtD
Brimonidine—Fatigue—Docetaxel—prostate cancer	4.65e-05	0.000367	CcSEcCtD
Brimonidine—Angiopathy—Epirubicin—prostate cancer	4.64e-05	0.000367	CcSEcCtD
Brimonidine—Nausea—Mitoxantrone—prostate cancer	4.63e-05	0.000366	CcSEcCtD
Brimonidine—Immune system disorder—Epirubicin—prostate cancer	4.62e-05	0.000365	CcSEcCtD
Brimonidine—Infection—Prednisone—prostate cancer	4.62e-05	0.000365	CcSEcCtD
Brimonidine—Mediastinal disorder—Epirubicin—prostate cancer	4.61e-05	0.000364	CcSEcCtD
Brimonidine—Pain—Docetaxel—prostate cancer	4.61e-05	0.000364	CcSEcCtD
Brimonidine—Dyspepsia—Capecitabine—prostate cancer	4.59e-05	0.000363	CcSEcCtD
Brimonidine—Pruritus—Etoposide—prostate cancer	4.59e-05	0.000362	CcSEcCtD
Brimonidine—Shock—Prednisone—prostate cancer	4.57e-05	0.000361	CcSEcCtD
Brimonidine—Arrhythmia—Epirubicin—prostate cancer	4.57e-05	0.000361	CcSEcCtD
Brimonidine—Visual impairment—Doxorubicin—prostate cancer	4.56e-05	0.00036	CcSEcCtD
Brimonidine—Nervous system disorder—Prednisone—prostate cancer	4.56e-05	0.00036	CcSEcCtD
Brimonidine—Tachycardia—Prednisone—prostate cancer	4.54e-05	0.000358	CcSEcCtD
Brimonidine—Skin disorder—Prednisone—prostate cancer	4.51e-05	0.000356	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Capecitabine—prostate cancer	4.5e-05	0.000356	CcSEcCtD
Brimonidine—Fatigue—Capecitabine—prostate cancer	4.5e-05	0.000355	CcSEcCtD
Brimonidine—Mental disorder—Epirubicin—prostate cancer	4.48e-05	0.000354	CcSEcCtD
Brimonidine—Pain—Capecitabine—prostate cancer	4.46e-05	0.000352	CcSEcCtD
Brimonidine—Erythema—Epirubicin—prostate cancer	4.45e-05	0.000352	CcSEcCtD
Brimonidine—Eye disorder—Doxorubicin—prostate cancer	4.42e-05	0.000349	CcSEcCtD
Brimonidine—Flushing—Doxorubicin—prostate cancer	4.39e-05	0.000347	CcSEcCtD
Brimonidine—Cardiac disorder—Doxorubicin—prostate cancer	4.39e-05	0.000347	CcSEcCtD
Brimonidine—Dysgeusia—Epirubicin—prostate cancer	4.36e-05	0.000344	CcSEcCtD
Brimonidine—Angiopathy—Doxorubicin—prostate cancer	4.3e-05	0.000339	CcSEcCtD
Brimonidine—Dizziness—Etoposide—prostate cancer	4.29e-05	0.000339	CcSEcCtD
Brimonidine—Immune system disorder—Doxorubicin—prostate cancer	4.28e-05	0.000338	CcSEcCtD
Brimonidine—Mediastinal disorder—Doxorubicin—prostate cancer	4.27e-05	0.000337	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Prednisone—prostate cancer	4.23e-05	0.000334	CcSEcCtD
Brimonidine—Arrhythmia—Doxorubicin—prostate cancer	4.23e-05	0.000334	CcSEcCtD
Brimonidine—Insomnia—Prednisone—prostate cancer	4.2e-05	0.000332	CcSEcCtD
Brimonidine—Vision blurred—Epirubicin—prostate cancer	4.2e-05	0.000331	CcSEcCtD
Brimonidine—Paraesthesia—Prednisone—prostate cancer	4.17e-05	0.00033	CcSEcCtD
Brimonidine—Mental disorder—Doxorubicin—prostate cancer	4.15e-05	0.000327	CcSEcCtD
Brimonidine—Erythema—Doxorubicin—prostate cancer	4.12e-05	0.000325	CcSEcCtD
Brimonidine—Dyspepsia—Prednisone—prostate cancer	4.09e-05	0.000323	CcSEcCtD
Brimonidine—Rash—Etoposide—prostate cancer	4.09e-05	0.000323	CcSEcCtD
Brimonidine—Dermatitis—Etoposide—prostate cancer	4.08e-05	0.000323	CcSEcCtD
Brimonidine—Headache—Etoposide—prostate cancer	4.06e-05	0.000321	CcSEcCtD
Brimonidine—Dysgeusia—Doxorubicin—prostate cancer	4.04e-05	0.000319	CcSEcCtD
Brimonidine—Fatigue—Prednisone—prostate cancer	4.01e-05	0.000316	CcSEcCtD
Brimonidine—Syncope—Epirubicin—prostate cancer	3.99e-05	0.000315	CcSEcCtD
Brimonidine—Hypersensitivity—Docetaxel—prostate cancer	3.97e-05	0.000313	CcSEcCtD
Brimonidine—Palpitations—Epirubicin—prostate cancer	3.94e-05	0.000311	CcSEcCtD
Brimonidine—Loss of consciousness—Epirubicin—prostate cancer	3.91e-05	0.000309	CcSEcCtD
Brimonidine—Cough—Epirubicin—prostate cancer	3.89e-05	0.000307	CcSEcCtD
Brimonidine—Vision blurred—Doxorubicin—prostate cancer	3.88e-05	0.000307	CcSEcCtD
Brimonidine—Asthenia—Docetaxel—prostate cancer	3.87e-05	0.000305	CcSEcCtD
Brimonidine—Nausea—Etoposide—prostate cancer	3.85e-05	0.000304	CcSEcCtD
Brimonidine—Hypertension—Epirubicin—prostate cancer	3.85e-05	0.000304	CcSEcCtD
Brimonidine—Hypersensitivity—Capecitabine—prostate cancer	3.84e-05	0.000304	CcSEcCtD
Brimonidine—Pruritus—Docetaxel—prostate cancer	3.81e-05	0.000301	CcSEcCtD
Brimonidine—Arthralgia—Epirubicin—prostate cancer	3.79e-05	0.000299	CcSEcCtD
Brimonidine—Chest pain—Epirubicin—prostate cancer	3.79e-05	0.000299	CcSEcCtD
Brimonidine—Myalgia—Epirubicin—prostate cancer	3.79e-05	0.000299	CcSEcCtD
Brimonidine—Anxiety—Epirubicin—prostate cancer	3.78e-05	0.000298	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	3.77e-05	0.000297	CcSEcCtD
Brimonidine—Discomfort—Epirubicin—prostate cancer	3.75e-05	0.000296	CcSEcCtD
Brimonidine—Asthenia—Capecitabine—prostate cancer	3.74e-05	0.000296	CcSEcCtD
Brimonidine—Dry mouth—Epirubicin—prostate cancer	3.71e-05	0.000293	CcSEcCtD
Brimonidine—Syncope—Doxorubicin—prostate cancer	3.7e-05	0.000292	CcSEcCtD
Brimonidine—Pruritus—Capecitabine—prostate cancer	3.69e-05	0.000291	CcSEcCtD
Brimonidine—Palpitations—Doxorubicin—prostate cancer	3.64e-05	0.000288	CcSEcCtD
Brimonidine—Oedema—Epirubicin—prostate cancer	3.63e-05	0.000287	CcSEcCtD
Brimonidine—Loss of consciousness—Doxorubicin—prostate cancer	3.62e-05	0.000286	CcSEcCtD
Brimonidine—Infection—Epirubicin—prostate cancer	3.61e-05	0.000285	CcSEcCtD
Brimonidine—Cough—Doxorubicin—prostate cancer	3.6e-05	0.000284	CcSEcCtD
Brimonidine—Shock—Epirubicin—prostate cancer	3.58e-05	0.000282	CcSEcCtD
Brimonidine—Nervous system disorder—Epirubicin—prostate cancer	3.56e-05	0.000281	CcSEcCtD
Brimonidine—Dizziness—Docetaxel—prostate cancer	3.56e-05	0.000281	CcSEcCtD
Brimonidine—Hypertension—Doxorubicin—prostate cancer	3.56e-05	0.000281	CcSEcCtD
Brimonidine—Tachycardia—Epirubicin—prostate cancer	3.55e-05	0.00028	CcSEcCtD
Brimonidine—Skin disorder—Epirubicin—prostate cancer	3.53e-05	0.000279	CcSEcCtD
Brimonidine—Arthralgia—Doxorubicin—prostate cancer	3.51e-05	0.000277	CcSEcCtD
Brimonidine—Chest pain—Doxorubicin—prostate cancer	3.51e-05	0.000277	CcSEcCtD
Brimonidine—Myalgia—Doxorubicin—prostate cancer	3.51e-05	0.000277	CcSEcCtD
Brimonidine—Anxiety—Doxorubicin—prostate cancer	3.5e-05	0.000276	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	3.48e-05	0.000275	CcSEcCtD
Brimonidine—Discomfort—Doxorubicin—prostate cancer	3.47e-05	0.000274	CcSEcCtD
Brimonidine—Dizziness—Capecitabine—prostate cancer	3.45e-05	0.000272	CcSEcCtD
Brimonidine—Dry mouth—Doxorubicin—prostate cancer	3.43e-05	0.000271	CcSEcCtD
Brimonidine—Hypersensitivity—Prednisone—prostate cancer	3.42e-05	0.00027	CcSEcCtD
Brimonidine—Rash—Docetaxel—prostate cancer	3.4e-05	0.000268	CcSEcCtD
Brimonidine—Hypotension—Epirubicin—prostate cancer	3.4e-05	0.000268	CcSEcCtD
Brimonidine—Dermatitis—Docetaxel—prostate cancer	3.39e-05	0.000268	CcSEcCtD
Brimonidine—Headache—Docetaxel—prostate cancer	3.38e-05	0.000267	CcSEcCtD
Brimonidine—Oedema—Doxorubicin—prostate cancer	3.36e-05	0.000266	CcSEcCtD
Brimonidine—Infection—Doxorubicin—prostate cancer	3.34e-05	0.000264	CcSEcCtD
Brimonidine—Asthenia—Prednisone—prostate cancer	3.33e-05	0.000263	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Epirubicin—prostate cancer	3.31e-05	0.000261	CcSEcCtD
Brimonidine—Shock—Doxorubicin—prostate cancer	3.31e-05	0.000261	CcSEcCtD
Brimonidine—Nervous system disorder—Doxorubicin—prostate cancer	3.3e-05	0.00026	CcSEcCtD
Brimonidine—Rash—Capecitabine—prostate cancer	3.29e-05	0.00026	CcSEcCtD
Brimonidine—Pruritus—Prednisone—prostate cancer	3.29e-05	0.00026	CcSEcCtD
Brimonidine—Insomnia—Epirubicin—prostate cancer	3.29e-05	0.00026	CcSEcCtD
Brimonidine—Dermatitis—Capecitabine—prostate cancer	3.29e-05	0.00026	CcSEcCtD
Brimonidine—Tachycardia—Doxorubicin—prostate cancer	3.28e-05	0.000259	CcSEcCtD
Brimonidine—Headache—Capecitabine—prostate cancer	3.27e-05	0.000258	CcSEcCtD
Brimonidine—Skin disorder—Doxorubicin—prostate cancer	3.27e-05	0.000258	CcSEcCtD
Brimonidine—Paraesthesia—Epirubicin—prostate cancer	3.26e-05	0.000258	CcSEcCtD
Brimonidine—Dyspnoea—Epirubicin—prostate cancer	3.24e-05	0.000256	CcSEcCtD
Brimonidine—Somnolence—Epirubicin—prostate cancer	3.23e-05	0.000255	CcSEcCtD
Brimonidine—Nausea—Docetaxel—prostate cancer	3.2e-05	0.000253	CcSEcCtD
Brimonidine—Dyspepsia—Epirubicin—prostate cancer	3.2e-05	0.000253	CcSEcCtD
Brimonidine—Hypotension—Doxorubicin—prostate cancer	3.14e-05	0.000248	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Epirubicin—prostate cancer	3.14e-05	0.000248	CcSEcCtD
Brimonidine—Fatigue—Epirubicin—prostate cancer	3.13e-05	0.000247	CcSEcCtD
Brimonidine—Pain—Epirubicin—prostate cancer	3.11e-05	0.000245	CcSEcCtD
Brimonidine—Nausea—Capecitabine—prostate cancer	3.1e-05	0.000245	CcSEcCtD
Brimonidine—Dizziness—Prednisone—prostate cancer	3.07e-05	0.000243	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Doxorubicin—prostate cancer	3.06e-05	0.000242	CcSEcCtD
Brimonidine—Insomnia—Doxorubicin—prostate cancer	3.04e-05	0.00024	CcSEcCtD
Brimonidine—Paraesthesia—Doxorubicin—prostate cancer	3.02e-05	0.000238	CcSEcCtD
Brimonidine—Dyspnoea—Doxorubicin—prostate cancer	3e-05	0.000237	CcSEcCtD
Brimonidine—Somnolence—Doxorubicin—prostate cancer	2.99e-05	0.000236	CcSEcCtD
Brimonidine—Dyspepsia—Doxorubicin—prostate cancer	2.96e-05	0.000234	CcSEcCtD
Brimonidine—Rash—Prednisone—prostate cancer	2.93e-05	0.000231	CcSEcCtD
Brimonidine—Dermatitis—Prednisone—prostate cancer	2.93e-05	0.000231	CcSEcCtD
Brimonidine—Headache—Prednisone—prostate cancer	2.91e-05	0.00023	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.9e-05	0.000229	CcSEcCtD
Brimonidine—Fatigue—Doxorubicin—prostate cancer	2.9e-05	0.000229	CcSEcCtD
Brimonidine—Pain—Doxorubicin—prostate cancer	2.88e-05	0.000227	CcSEcCtD
Brimonidine—Nausea—Prednisone—prostate cancer	2.76e-05	0.000218	CcSEcCtD
Brimonidine—Hypersensitivity—Epirubicin—prostate cancer	2.68e-05	0.000211	CcSEcCtD
Brimonidine—Asthenia—Epirubicin—prostate cancer	2.61e-05	0.000206	CcSEcCtD
Brimonidine—Pruritus—Epirubicin—prostate cancer	2.57e-05	0.000203	CcSEcCtD
Brimonidine—Hypersensitivity—Doxorubicin—prostate cancer	2.48e-05	0.000196	CcSEcCtD
Brimonidine—Asthenia—Doxorubicin—prostate cancer	2.41e-05	0.000191	CcSEcCtD
Brimonidine—Dizziness—Epirubicin—prostate cancer	2.4e-05	0.00019	CcSEcCtD
Brimonidine—Pruritus—Doxorubicin—prostate cancer	2.38e-05	0.000188	CcSEcCtD
Brimonidine—Rash—Epirubicin—prostate cancer	2.29e-05	0.000181	CcSEcCtD
Brimonidine—Dermatitis—Epirubicin—prostate cancer	2.29e-05	0.000181	CcSEcCtD
Brimonidine—Headache—Epirubicin—prostate cancer	2.28e-05	0.00018	CcSEcCtD
Brimonidine—Dizziness—Doxorubicin—prostate cancer	2.22e-05	0.000176	CcSEcCtD
Brimonidine—Nausea—Epirubicin—prostate cancer	2.16e-05	0.00017	CcSEcCtD
Brimonidine—Rash—Doxorubicin—prostate cancer	2.12e-05	0.000167	CcSEcCtD
Brimonidine—Dermatitis—Doxorubicin—prostate cancer	2.12e-05	0.000167	CcSEcCtD
Brimonidine—Headache—Doxorubicin—prostate cancer	2.11e-05	0.000166	CcSEcCtD
Brimonidine—Nausea—Doxorubicin—prostate cancer	2e-05	0.000158	CcSEcCtD
Brimonidine—ADRA2B—Signaling Pathways—LPL—prostate cancer	6.18e-06	0.000149	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—IL2—prostate cancer	6.14e-06	0.000148	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PDGFRB—prostate cancer	6.13e-06	0.000148	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ITPR1—prostate cancer	6.12e-06	0.000148	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PPARA—prostate cancer	6.1e-06	0.000147	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PIK3CB—prostate cancer	6.07e-06	0.000146	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IGF1R—prostate cancer	6.03e-06	0.000145	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—PIK3CA—prostate cancer	6.02e-06	0.000145	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CG—prostate cancer	6.01e-06	0.000145	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—CXCL8—prostate cancer	6e-06	0.000145	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ITGB3—prostate cancer	5.97e-06	0.000144	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—JAK2—prostate cancer	5.97e-06	0.000144	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CASP9—prostate cancer	5.94e-06	0.000143	CbGpPWpGaD
Brimonidine—AOX1—Disease—IL6—prostate cancer	5.92e-06	0.000143	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—CXCL8—prostate cancer	5.83e-06	0.000141	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—TP53—prostate cancer	5.83e-06	0.000141	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3CD—prostate cancer	5.82e-06	0.00014	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ERBB3—prostate cancer	5.79e-06	0.00014	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—FGFR2—prostate cancer	5.79e-06	0.00014	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—TYMS—prostate cancer	5.78e-06	0.00014	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—LPL—prostate cancer	5.78e-06	0.000139	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NGFR—prostate cancer	5.76e-06	0.000139	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PRKCQ—prostate cancer	5.76e-06	0.000139	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—TGFB1—prostate cancer	5.75e-06	0.000139	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CAV1—prostate cancer	5.74e-06	0.000138	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—IL2—prostate cancer	5.73e-06	0.000138	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PDGFRB—prostate cancer	5.73e-06	0.000138	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—GSTM1—prostate cancer	5.72e-06	0.000138	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MAP3K7—prostate cancer	5.69e-06	0.000137	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PIK3CB—prostate cancer	5.67e-06	0.000137	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—LPL—prostate cancer	5.61e-06	0.000135	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—PIK3CA—prostate cancer	5.6e-06	0.000135	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ITGB3—prostate cancer	5.58e-06	0.000135	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—IL2—prostate cancer	5.57e-06	0.000134	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TERT—prostate cancer	5.55e-06	0.000134	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FGF10—prostate cancer	5.47e-06	0.000132	CbGpPWpGaD
Brimonidine—AOX1—Disease—AKT1—prostate cancer	5.46e-06	0.000132	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—CXCL8—prostate cancer	5.45e-06	0.000131	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CYP1A1—prostate cancer	5.42e-06	0.000131	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ADRB2—prostate cancer	5.41e-06	0.000131	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ERBB3—prostate cancer	5.41e-06	0.000131	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—FGFR2—prostate cancer	5.4e-06	0.00013	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ERCC2—prostate cancer	5.38e-06	0.00013	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—JAK2—prostate cancer	5.34e-06	0.000129	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—KRAS—prostate cancer	5.32e-06	0.000128	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—MAP2K1—prostate cancer	5.32e-06	0.000128	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—HIF1A—prostate cancer	5.31e-06	0.000128	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CD—prostate cancer	5.28e-06	0.000127	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—VAV3—prostate cancer	5.28e-06	0.000127	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—AKT1—prostate cancer	5.27e-06	0.000127	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CG—prostate cancer	5.23e-06	0.000126	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—IL2—prostate cancer	5.21e-06	0.000126	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TGFBR2—prostate cancer	5.2e-06	0.000125	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TERT—prostate cancer	5.19e-06	0.000125	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—LEP—prostate cancer	5.18e-06	0.000125	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CAV1—prostate cancer	5.14e-06	0.000124	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ITPR1—prostate cancer	5.12e-06	0.000123	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—KDR—prostate cancer	5.08e-06	0.000123	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3CB—prostate cancer	5.07e-06	0.000122	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—MTHFR—prostate cancer	5.05e-06	0.000122	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—HIF1A—prostate cancer	4.96e-06	0.00012	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PPARA—prostate cancer	4.96e-06	0.00012	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ESR1—prostate cancer	4.95e-06	0.000119	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—INS—prostate cancer	4.95e-06	0.000119	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—AKT1—prostate cancer	4.92e-06	0.000119	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IGF1R—prostate cancer	4.89e-06	0.000118	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—PIK3CA—prostate cancer	4.89e-06	0.000118	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—CXCL8—prostate cancer	4.87e-06	0.000118	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—JAK2—prostate cancer	4.85e-06	0.000117	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CREBBP—prostate cancer	4.85e-06	0.000117	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—LEP—prostate cancer	4.84e-06	0.000117	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—BAD—prostate cancer	4.83e-06	0.000117	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CAV1—prostate cancer	4.8e-06	0.000116	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—KDR—prostate cancer	4.74e-06	0.000114	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—TP53—prostate cancer	4.73e-06	0.000114	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—LPL—prostate cancer	4.69e-06	0.000113	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CG—prostate cancer	4.68e-06	0.000113	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—APC—prostate cancer	4.68e-06	0.000113	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CAV1—prostate cancer	4.66e-06	0.000112	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—IL2—prostate cancer	4.66e-06	0.000112	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PDGFRB—prostate cancer	4.65e-06	0.000112	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—EGF—prostate cancer	4.62e-06	0.000112	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IRS1—prostate cancer	4.62e-06	0.000112	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ESR1—prostate cancer	4.62e-06	0.000112	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CB—prostate cancer	4.6e-06	0.000111	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CD—prostate cancer	4.59e-06	0.000111	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—AKT1—prostate cancer	4.57e-06	0.00011	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ITGB3—prostate cancer	4.53e-06	0.000109	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—BAD—prostate cancer	4.51e-06	0.000109	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—GSK3B—prostate cancer	4.49e-06	0.000108	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—INS—prostate cancer	4.43e-06	0.000107	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CXCL8—prostate cancer	4.42e-06	0.000107	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ERBB3—prostate cancer	4.4e-06	0.000106	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FGFR2—prostate cancer	4.39e-06	0.000106	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CG—prostate cancer	4.37e-06	0.000105	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—APC—prostate cancer	4.37e-06	0.000105	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—NOS3—prostate cancer	4.34e-06	0.000105	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CREBBP—prostate cancer	4.34e-06	0.000105	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—EGF—prostate cancer	4.32e-06	0.000104	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IRS1—prostate cancer	4.32e-06	0.000104	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IGF1—prostate cancer	4.28e-06	0.000103	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—EGFR—prostate cancer	4.26e-06	0.000103	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CG—prostate cancer	4.25e-06	0.000102	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—IL2—prostate cancer	4.23e-06	0.000102	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TERT—prostate cancer	4.21e-06	0.000102	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—GSK3B—prostate cancer	4.19e-06	0.000101	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MAP2K1—prostate cancer	4.14e-06	9.99e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—INS—prostate cancer	4.14e-06	9.98e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CD—prostate cancer	4.11e-06	9.92e-05	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—PIK3CA—prostate cancer	4.07e-06	9.83e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—SERPINE1—prostate cancer	4.07e-06	9.81e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CREBBP—prostate cancer	4.05e-06	9.77e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HIF1A—prostate cancer	4.03e-06	9.72e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—KRAS—prostate cancer	4.03e-06	9.71e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—INS—prostate cancer	4.02e-06	9.69e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CB—prostate cancer	4e-06	9.66e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IGF1—prostate cancer	4e-06	9.65e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—AKT1—prostate cancer	4e-06	9.64e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—EGFR—prostate cancer	3.98e-06	9.6e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PTGS2—prostate cancer	3.97e-06	9.57e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—FGF2—prostate cancer	3.94e-06	9.5e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CREBBP—prostate cancer	3.94e-06	9.49e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—LEP—prostate cancer	3.93e-06	9.49e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CAV1—prostate cancer	3.9e-06	9.4e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NOS3—prostate cancer	3.88e-06	9.37e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MAP2K1—prostate cancer	3.87e-06	9.33e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—KDR—prostate cancer	3.85e-06	9.3e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CD—prostate cancer	3.84e-06	9.27e-05	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—PIK3CA—prostate cancer	3.81e-06	9.18e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SERPINE1—prostate cancer	3.8e-06	9.17e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—JAK2—prostate cancer	3.77e-06	9.11e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—KRAS—prostate cancer	3.76e-06	9.07e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ESR1—prostate cancer	3.76e-06	9.06e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CD—prostate cancer	3.73e-06	9e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PIK3CA—prostate cancer	3.7e-06	8.92e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MDM2—prostate cancer	3.68e-06	8.89e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—FGF2—prostate cancer	3.68e-06	8.87e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—BAD—prostate cancer	3.67e-06	8.84e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ERBB2—prostate cancer	3.63e-06	8.76e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NOS3—prostate cancer	3.63e-06	8.75e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CB—prostate cancer	3.59e-06	8.65e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CG—prostate cancer	3.55e-06	8.56e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—APC—prostate cancer	3.55e-06	8.56e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—JAK2—prostate cancer	3.53e-06	8.51e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—NOS3—prostate cancer	3.52e-06	8.5e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IRS1—prostate cancer	3.51e-06	8.46e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—EGF—prostate cancer	3.51e-06	8.46e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PTEN—prostate cancer	3.46e-06	8.35e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PIK3CA—prostate cancer	3.46e-06	8.34e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CXCL8—prostate cancer	3.45e-06	8.31e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MDM2—prostate cancer	3.44e-06	8.3e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—GSK3B—prostate cancer	3.41e-06	8.22e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ERBB2—prostate cancer	3.39e-06	8.19e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CDKN1B—prostate cancer	3.36e-06	8.12e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—INS—prostate cancer	3.36e-06	8.11e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CB—prostate cancer	3.35e-06	8.08e-05	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—AKT1—prostate cancer	3.33e-06	8.03e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—EP300—prostate cancer	3.3e-06	7.96e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CASP3—prostate cancer	3.3e-06	7.95e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IL2—prostate cancer	3.29e-06	7.94e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CREBBP—prostate cancer	3.29e-06	7.94e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—IL6—prostate cancer	3.28e-06	7.9e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CB—prostate cancer	3.25e-06	7.85e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IGF1—prostate cancer	3.25e-06	7.84e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—EGFR—prostate cancer	3.23e-06	7.8e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PTGS2—prostate cancer	3.22e-06	7.77e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CXCL8—prostate cancer	3.22e-06	7.76e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CCND1—prostate cancer	3.21e-06	7.74e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CTNNB1—prostate cancer	3.18e-06	7.67e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CDKN1B—prostate cancer	3.14e-06	7.58e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MAP2K1—prostate cancer	3.14e-06	7.58e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CD—prostate cancer	3.12e-06	7.53e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MMP9—prostate cancer	3.12e-06	7.52e-05	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—AKT1—prostate cancer	3.11e-06	7.5e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CDKN1A—prostate cancer	3.1e-06	7.49e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PTEN—prostate cancer	3.1e-06	7.47e-05	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3CA—prostate cancer	3.09e-06	7.46e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SERPINE1—prostate cancer	3.09e-06	7.45e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CASP3—prostate cancer	3.08e-06	7.43e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IL2—prostate cancer	3.08e-06	7.42e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—IL6—prostate cancer	3.06e-06	7.38e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—KRAS—prostate cancer	3.06e-06	7.37e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—AKT1—prostate cancer	3.02e-06	7.29e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CCND1—prostate cancer	3e-06	7.23e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FGF2—prostate cancer	2.99e-06	7.21e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CTNNB1—prostate cancer	2.97e-06	7.16e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—EP300—prostate cancer	2.95e-06	7.13e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NOS3—prostate cancer	2.95e-06	7.11e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MMP9—prostate cancer	2.91e-06	7.02e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CDKN1A—prostate cancer	2.9e-06	7e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PTEN—prostate cancer	2.89e-06	6.98e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—SRC—prostate cancer	2.87e-06	6.93e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—JAK2—prostate cancer	2.86e-06	6.91e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—AKT1—prostate cancer	2.82e-06	6.81e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PTEN—prostate cancer	2.81e-06	6.78e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CA—prostate cancer	2.81e-06	6.77e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—VEGFA—prostate cancer	2.8e-06	6.75e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MDM2—prostate cancer	2.8e-06	6.74e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—STAT3—prostate cancer	2.77e-06	6.68e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—EP300—prostate cancer	2.76e-06	6.66e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ERBB2—prostate cancer	2.76e-06	6.65e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CB—prostate cancer	2.72e-06	6.56e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SRC—prostate cancer	2.68e-06	6.47e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—EP300—prostate cancer	2.68e-06	6.47e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CXCL8—prostate cancer	2.61e-06	6.31e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—VEGFA—prostate cancer	2.61e-06	6.3e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—STAT3—prostate cancer	2.59e-06	6.24e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MYC—prostate cancer	2.57e-06	6.21e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TGFB1—prostate cancer	2.57e-06	6.19e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	2.55e-06	6.16e-05	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	2.53e-06	6.09e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—EGFR—prostate cancer	2.52e-06	6.07e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CASP3—prostate cancer	2.5e-06	6.03e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IL2—prostate cancer	2.5e-06	6.03e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—IL6—prostate cancer	2.49e-06	6e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CA—prostate cancer	2.44e-06	5.89e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CCND1—prostate cancer	2.44e-06	5.87e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	2.41e-06	5.82e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MYC—prostate cancer	2.4e-06	5.8e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TGFB1—prostate cancer	2.4e-06	5.79e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—KRAS—prostate cancer	2.38e-06	5.74e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MMP9—prostate cancer	2.36e-06	5.7e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	2.36e-06	5.68e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—EGFR—prostate cancer	2.35e-06	5.67e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PTEN—prostate cancer	2.35e-06	5.67e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	2.29e-06	5.53e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—EP300—prostate cancer	2.24e-06	5.41e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—KRAS—prostate cancer	2.22e-06	5.36e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CA—prostate cancer	2.19e-06	5.27e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SRC—prostate cancer	2.18e-06	5.26e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	2.12e-06	5.12e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TP53—prostate cancer	2.11e-06	5.1e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—STAT3—prostate cancer	2.1e-06	5.07e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CA—prostate cancer	2.04e-06	4.92e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—AKT1—prostate cancer	1.99e-06	4.81e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CA—prostate cancer	1.98e-06	4.78e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TP53—prostate cancer	1.97e-06	4.76e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MYC—prostate cancer	1.95e-06	4.71e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	1.95e-06	4.7e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IL6—prostate cancer	1.94e-06	4.67e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—EGFR—prostate cancer	1.91e-06	4.61e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IL6—prostate cancer	1.81e-06	4.36e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—KRAS—prostate cancer	1.8e-06	4.35e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—AKT1—prostate cancer	1.79e-06	4.31e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—AKT1—prostate cancer	1.67e-06	4.02e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	1.66e-06	4e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—AKT1—prostate cancer	1.62e-06	3.91e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TP53—prostate cancer	1.6e-06	3.87e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IL6—prostate cancer	1.47e-06	3.54e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AKT1—prostate cancer	1.35e-06	3.27e-05	CbGpPWpGaD
